Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of actiponin on antiobesity in obese korean subjects.

Conditions: Obesity

Summary: obesity is a major health issue worldwide; there is a constant raise in obesity related death each year. in vitro and animal studies elucidated actiponin as a novel anti-obesity agent. however, the efficacy and safety of actiponin supplementation on body weight regulation in humans are lacking.

the primary aim of the study was to investigate the effect of actiponin in korean subjects on body weight and fat loss along with changes in metabolic markers based on 12 week, randomized, double-blind, placebo-controlled clinical trial. eighty obesity subjects with bmi \> 25kg/m2 and waist-hip ratio (whr) ≥ 0.90 for men and ≥ 0.85 for women were randomly divided into either actiponin (n=40, 450mg/day) or placebo group (n=40, 450mg/day) for 12weeks.

Eligibility criteria:
inclusion criteria: * bmi ≥ 25kg/m2 and whr ≥ 0.90(men), whr ≥ 0.85(women) exclusion criteria: * significant variation in weight(more 10%) in the past 3 months * cardiovascular disease, e.g. arrhythmia, heart failure, myocardial infarction, and patient with pacemaker * history of disease that could interfere with the test products or impede theire absorption, such as gastrointestinal disease or gastrointestinal surgery * participation in any other clinical trials within past 2 months * abdominal hepatic liver function * renal disease, e.g. acute/chronic renal failure, nephritic syndrome * used antipsychosis drugs therapy within past 2 months * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * pregnancy or breast feeding * history of alcohol or substance abuse * allergic or hypersensitive to any of the ingredients in the test products

Keywords: actiponin obesity abdominal fat
transcranial magnetic stimulation for restricted and repetitive behavior in asd

Conditions: Autism Spectrum Disorder; Autism; Asperger Syndrome

Summary: investigating the efficacy of a form of tms called theta-burst stimulation for restricted and repetitive behavior in asd.


Eligibility criteria:
inclusion criteria: 1. diagnosis of autism spectrum disorder (asd), asperger's or autism. 2. meet criteria for asd on clinical assessments (ados-2 or cars/bosa if conducted remotely \& adi-r) 3. aged between 12-45 years old 4. have a reliable informant who can complete relevant questionnaires 5. must have previously not responded or not tolerated 2 treatments. exclusion criteria: 1. any contraindications for tms e.g. history of seizures 2. pregnancy 3. any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. 4. active substance use (\<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines 5. showing symptoms of withdrawal from alcohol or benzodiazepines 6. dsm-5 diagnosis of bipolar disorder or a psychotic disorder e.g. schizophrenia. 7. significant sensory impairments such as blindness or deafness. 8. any other indication the pi feels would comprise data 9. current severe insomnia (must sleep a minimum of 4 hours the night before stimulation) 10. iq\<50 or not testable using iq measures and no historical iq score available 11. currently taking clozapine or another medication that the pi determines increases the risk of tms or may disrupt the efficacy. 12. a motor threshold that is too high to allow safe/tolerable treatment.
clinical utility of rapid ct/ng testing in the ed

Conditions: Sexually Transmitted Diseases

Summary: the purpose of this study is to: 1. determine the clinical impact of rapid chlamydia trachomatis (ct), neisseria gonorrhoeae (ng) testing on antibiotic over and under treatment for ct/ng in women evaluated in the emergency department (ed) for a sexually transmitted infection (sti). 2. determine the clinical impact of rapid trichomonas vaginalis (tv) testing on antibiotic under and over treatment for tv in women evaluated in the ed for an sti 3. evaluate the feasibility of integrating rapid chlamydia trachomatis (ct), neisseria gonorrhoeae (ng) and tv testing in the emergency department setting. to evaluate the impact or rapid ct/ng/tv testing an patient comprehension of sexually transmitted infection diagnosis.


Eligibility criteria:
inclusion criteria: * the study population includes women between the age of 18 and 50 who present to the ed and are going to receive ct/ng testing in the ed. exclusion criteria: * patients will be excluded if they are unable to provide informed consent or are not english speaking.
histopathology images based survival prediction of glioma patients using artificial intelligence

Conditions: Glioma

Summary: this registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, mgmt methylation, idh and tertp mutations, etc) and images of he slices in primary gliomas. by leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

non-invasive and precise prediction for survivals of glioma patients is challenging. with the development of artificial intelligence, much more potential lies in the histopathology images of he slices in primary gliomas could be excavated to aid prediction of patients' prognosis in the frame of molecular pathology of gliomas. the creation of a registry for primary glioma with detailed survival data, molecular pathology, histopathology image data and with sufficient sample size for deep learning (\>1000) provides opportunities for personalized prediction of survival of glioma patients with non-invasiveness and precision.

Eligibility criteria:
inclusion criteria: * patients must have radiologically and histologically confirmed diagnosis of primary glioma * life expectancy of greater than 3 months * must receive tumor resection * signed informed consent exclusion criteria: * no gliomas * no sufficient amount of tumor tissues for detection of molecular pathology * patients who are pregnant or breast feeding * patients who are suffered from severe systematic malfuctions

Keywords: prognosis histopathology imaging deep learning machine learning
cardiovascular and metabolic sciences biorepository

Conditions: Cardiovascular Diseases; Metabolic Disease

Summary: the purpose of the cardiovascular and metabolic sciences biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.

heart disease is the leading cause of death in the united states and other vascular diseases, like stroke, and metabolic diseases, like diabetes, are consistently in the top ten causes of death (cdc, 2024). there is clearly a need for continuing research and innovation into improved diagnosis and treatment of these diseases. the goal of this biorepository is to provide an easily accessible collection of samples for researchers to utilize. the biorepository will also serve as a place to store residual samples from other cardiovascular disease (cvd) studies for future use, to make the best use of these biospecimen resources.

Eligibility criteria:
inclusion criteria: * willing and able to sign the informed consent document exclusion criteria: * chronic anemia (hemoglobin consistently \<9 g/l)

Keywords: biorepository
multicenter randomized double-blind study evaluating the effects of botulinum toxin a associated with ropivacaïne versus ropivacaïne alone in the treatment of the myofascial pelviperineal pain

Conditions: Myofascial Pelviperineal Pain

Summary: myofascial pains are frequently found during the clinical examination of the patients presenting a painful chronic syndrome of the pelvis or the perineum. if the physiopathology of this component of the pain characterized by triggerpoints found in the clinical examination, remains uncertain; its coverage contributes to the improvement of the global pain of the patient. the physiotherapy can be useful but when it is not useful, we proposed injections of triggerpoints by local anesthetics. the injections of botulinum toxin on these triggerpoints have a legitimacy (action on the muscular cramp and action on the afferent fibers) but are they superior to the injections of local anesthetics of triggerpoints? the literature remains poor on the subject, justifying this randomized double-blind protocol comparing the efficacy of the botulinum toxin associated with a local anesthetic versus local anesthetic alone with a main criterion of evaluation in 2 months and a monthly follow-up as long as the patient remains improved and maximum in 6 months.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patient presenting a "dysfunctional" pain of the pelvis or the perineum (without lesional pathology justifying a specific treatment) by an endopelvic touch * pain evolving since at least 6 months and persisting in spite of the analgesic treatments and the physiotherapy * patient presenting to the clinical examination one or several active triggerpoints found on the internal obturating muscles and/or elevators of the anus, with a maximum of 10 triggerpoints on the whole body. * patient presenting an average of the maximal pains of the week before the inclusion superior or equal to 4 and inferior or equal to 9/10 (evaluation of the daily maximal pain on a digital scale from 0 to 10) * signed informed consent * subjects affiliated with an appropriate social security system exclusion criteria: * patients with bleeding risk and anticoagulant therapy * intolerance of botulinum toxin a, ropivacaïne and nitrous oxide * injection of botulinum toxin in any place whatsoever in the previous 3 months * pregnancy and breast feeding * antibiotic treatment by aminoglycosides * recent anti-inflammatory treatment * severe myasthenia * lambert-eaton syndrome * patients with neurological disorders, dysphagia, food choking or inhalation pneumonia * beck score \> 16 * patients having an average of the maximal pains of the previous week lower than 4

Keywords: myofascial pain perineal pain chronic pelvic pain botulinum toxin type a ropivacaïne
safety and efficacy of cd5024 0.3% cream in subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of atopic dermatitis (ad) to evaluate the local and systemic safety of cd5024 0.3% cream over a 6-week treatment period compared to its vehicle.

study application was performed once daily, 7 days a week for 6 weeks.

Eligibility criteria:
inclusion criteria: 1. the participant was a male or female aged 18 to 60 years old inclusive at screening. 2. the participant presented with a total body surface area (tbsa) less than or equal to (\>=) 2 square meter (m\^2) at screening. 3. the participant had atopic dermatitis for at least 6 months prior to day 1. the clinical diagnosis of atopic dermatitis must be confirmed with the criteria of hanifin and rajka at the screening visit. 4. atopic dermatitis must be stable for at least one month before the screening visit (according to participant). 5. the participant had a body surface area (bsa) affected by ad ranging from 1% inclusive to 10% inclusive at day 1, excluding scalp and genitals. 6. the participant had an overall investigator's global assessment (iga) score of 3 (moderate) at day 1; exclusion criteria: 1. the participant was a pregnant female, is breastfeeding or intends to conceive a child during the study, 2. the participant had any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results (e.g. extensive scaring or pigmented lesion in a treated area), and/or put the participant at significant risk according to investigator's judgment if he/she participates in the clinical trial (e.g. active cancer, aids, insulin-dependent diabetes...) at screening or day 1. 3. the participant presented with an acute flare of ad at day 1. 4. the participant had active cutaneous bacterial or viral infection in any treated area at baseline (e.g. clinically infected ad) at screening or day 1. 5. the participant had a history of confounding skin condition (e.g. psoriasis, erythroderma) or a history of netherton syndrome at screening. 6. the participant had a past history of serious persistent neurological disorders such as seizures, multiple sclerosis, or neurological signs or symptoms at screening.
a novel therapy for breast cancer survivors with genitourinary syndrome of menopause

Conditions: Breast Cancer; Genitourinary Syndrome of Menopause

Summary: the purpose of this study is to determine whether platelet rich plasma (prp) injections to the vulva and vagina will improve symptoms of genitourinary syndrome of menopause (gsm) in breast cancer patients.


Eligibility criteria:
inclusion criteria: * female patients who are age 18 years and older * patients must have a history of biopsy-proven ductal carcinoma in situ (dcis) or stage i-iii breast cancer and must be currently undergoing treatment or have completed primary treatment. * patients must be found to have a vaginal health index (vhi) score of \<15. * patients may be currently using endocrine therapy (ovarian function suppression, tamoxifen, or aromatase inhibitors). patients not currently using endocrine therapy will also be eligible for participation since patients more than 5 or 10 years from diagnosis (and therefore having completed adjuvant endocrine therapy) may be enrolled. * some patients with triple negative breast cancer who receive chemotherapy also experience gsm related to ovarian function decline outside of the setting of ovarian suppression, and therefore patients with either er+ or er- breast cancer will be allowed to participate. * patients must provide written informed consent for participation in this study. * patients are allowed to have used non-hormonal moisturizers but if they have previously used hormonal moisturizers, they will be asked to stop the use for one month prior to the first planned treatment, termed the "washout period", if needed. exclusion criteria: * patients with any systemic or topical hormone replacement therapy within 3 months prior to enrollment, known genital infection, coagulation disorders, or on anticoagulant therapy or turmeric-containing supplements within the prior 2 weeks will be excluded. * women who are pregnant or who plan to become pregnant within the following six months will be excluded since the impact of recent prp injections to the vulva and the impact on obstetric injury during vaginal delivery has not been studied.
hd patients' depression and happiness

Conditions: Hemodialysis

Summary: the aim of the study is to verify the mediating effect of life of meaning and post-traumatic growth in spirituality and psychological well-being (happiness, depression).

the research design is cross-sectional correlational study. convenient sampling will be used to conduct to data collection. there are 300 patients with hemodialysis from a hemodialysis institution in the north taiwan, and data collecting with self-administrated questionnaires. the instruments include demographic and disease-related information, spiritual health scale short form, chinese happiness inventory, beck depression inventory-ii, life attitude profile, posttraumatic growth inventory. the spss 22.0 statistical software will be used to analyze the data. descriptive statistics, such as frequency, percentage, mean, and standard deviation (sd) will be used for participant characteristics and outcome measures. t-test, chi-square, anova, post-hoc, ancova, and person's correlation will be conducted to test the relationships between the research variables.

Eligibility criteria:
inclusion criteria: * patients who are over 20 years old * voluntarily participate in the study and sign the respondent consent form * have received routine hemodialysis treatment for more than three months * have clear consciousness and can communicate in mandarin and taiwanese. exclusion criteria: * patients whose medical records record a diagnosis of schizophrenia * patients are taking antidepressant drugs

Keywords: spirituality depression happiness post-trauma growth life meaning
different factors affecting patients with newly diagnosed bladder cancer

Conditions: Bladder Cancer

Summary: rationale: studying different factors that effect patients with newly diagnosed bladder cancer may help doctors learn more about the disease, improve the ability to plan cancer treatment, and help patients live more comfortably. purpose: this clinical trial is studying different factors affecting patients with newly diagnosed bladder cancer.

objectives: * to assess the effect of lifestyle factors (e.g., smoking, dietary habits, fluid intake, or environmental exposures) on the recurrence and progression of bladder cancer. * to assess the impact of selenium and/or vitamin e on the progression and recurrence of bladder cancer. * to study health-related quality of life and its association with recurrence and progression of bladder cancer. * to establish a bladder cancer tissue bank that will comprise blood, urine, and bladder tissue. * to study the predictive effect of molecular markers on the recurrence and progression of bladder cancer. outline: this is a multicenter study. the study will be based on a cohort of patients with newly detected bladder cancer in all 16 urological centres within the west midlands, commencing in late 2005 for a period of 5 years. this research project consists of 5 individual studies: cruk-bcpp-2005-01-cohort, cruk-bcpp-2005-01-markers, cruk-bcpp-2005-01-qol, cruk-bcpp-2005-01-tissue-bank, and cruk-bcpp-2005-01-treatment. patients may participate in all or only some of these individual studies. peer reviewed and funded or endorsed by cancer research uk.

Eligibility criteria:
disease characteristics: * bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma meeting 1 of the following criteria: * non-muscle-invasive tumor * muscle-invasive tumor * solitary g1 pta tumor * no previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis patient characteristics: * fit for cystoscopy and surgical biopsy/resection * no hiv infection * no condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives prior concurrent therapy: * not specified

Keywords: stage 0 bladder cancer stage i bladder cancer stage ii bladder cancer transitional cell carcinoma of the bladder
a phase iii clinical study to evaluate the efficacy and safety of gzr18 injection in adult obese/overweight subjects

Conditions: Obesity/Overweight

Summary: this is a multicenter, randomized, double-blind, placebo-controlled phase iii clinical study in adult obese/overweight subjects in china to evaluate the efficacy and safety of gzr18 injection in the subjects.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years (as of the date of signing the informed consent form (icf)), male or female. * obese (bmi ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ bmi \< 28 kg/m2) with at least one comorbidity. * able to understand the procedures and methods in this study; willing and able to maintain a stable diet and exercise lifestyle during the research period, and willing to sign the icf voluntarily. * subjects of childbearing potential with no birth plan from the signing of icf to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm donation. females of childbearing potential must not be lactating and must have negative results of pregnancy tests at screening and visit 2 (before randomization). exclusion criteria: * known or suspected hypersensitivity to glucagon like peptide-1 receptor agonist (glp-1ra) drugs or excipients. * history of drug abuse prior to screening. * history of alcohol abuse within 6 months before screening. * weight change of \> 5.0% within 3 months before screening (self-report). * presence of limb deformity or mutilation affecting height measurement.
collection of head images during radiotherapy

Conditions: Head and Neck Neoplasms; Radiation Therapy Complication

Summary: the primary objective of this observational study is to quantify the translation, rotation, and deformation of patient head positions of head and neck cancer patients over the course of a radiation therapy treatment for head and neck cancer. this objective will be achieved by comparing x-ray images collected during each treatment session with those obtained from the planning ct scan. secondary objectives include (1) the use of the collected x-ray images to develop realistic artificial x-ray images where patient movement can be simulated and (2) to determine whether motion can be detected from individual x-ray images acquired during radiation therapy treatment.

participants will undergo their radiation therapy treatment for hnc as planned and per the routine clinical management protocol. as part of this routine treatment, multiple x-ray images will be acquired to assist in accurate positioning of the patient for their planned radiation therapy. normally these images are stored for a few days and then discarded. this study will be collating, storing and analysing these images. these x-ray images will be paired with the corresponding pre-treatment ct scan that is routinely acquired for each patient, as well as the locations of organs of interest, such as the tumour and surrounding structures. the patient treatment plan will also be collated, as it will allow for analysis of how any motion affects the accuracy of dose delivery. the patient radiation treatment delivery record will be collected to help sort and categorise the acquired images. information on potential confounding or interacting factors will be collected: demographic information will be collected including sex, age, tumour stage and histology.

Eligibility criteria:
inclusion criteria: * a diagnosis of head and neck cancer (any stage) * age 18 years or greater * receiving radiation therapy to the head and neck with a thermoplastic immobilisation mask * an ecog score in the range of 0 to 2 * any other prior or concurrent therapy allowed exclusion criteria: * people with cognitive impairment which would preclude them from providing informed consent * people who are unable to speak and read english and for whom obtaining consent would be difficult.